Patient identification, determination and treatment methods using proteasome inhibition therapy

• 收藏
• 分享

专利权人:

ファーマシューティカルズ，;インコーポレイテッド;ミレニアム;ミレニアム ファーマシューティカルズ, インコーポレイテッド

发明人:

ジョージ・マリガン,バーバラ・エム・ブライアント,マイケル・ピー・モリッシー,アンドリュー・ボルト,アンドリュー・アイ・ダモコッシュ

申请号：

JP2010092346

公开号：

JP5896593B2

申请日:

2010.04.13

申请国别(地区):

JP

年份:

2016

代理人:

摘要：

The present invention is directed to the identification of markers that can be used to determine whether patients with cancer are clinically responsive or non-responsive to a therapeutic regimen prior to treatment. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with responsiveness or non-responsiveness to a therapeutic regimen comprising proteasome inhibition. Thus, by examining the expression levels of individual markers and those comprising a marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of tumors in a clinical setting.

来源网站：

中国工程科技知识中心

来源网址：

http://www.ckcest.cn/home/